Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15976685 | 0.73 | ALDH1A1 (0.32) | — | |
| SCHEMBL10313767 | 0.71 | TSHR (0.34) | TDP1 | |
| SCHEMBL10957637 | 0.71 | — | — | |
| SCHEMBL5041274 | 0.69 | — | — | |
| SCHEMBL13274159 | 0.67 | — | — | |
| SCHEMBL13684880 | 0.67 | — | — | |
| SCHEMBL14540926 | 0.67 | — | — | |
| SCHEMBL17465776 | 0.67 | THRB (0.31) | — | |
| SCHEMBL16701997 | 0.67 | TDP1 (0.34) | TDP1 | |
| SCHEMBL14387614 | 0.67 | VCAM1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169204-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| EP-2720546-B1 | SPIRO-CYCLIC TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| EP-2721016-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| WO-2015159233-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-10-22 | — | — | WO | disclosed |
| EP-2445345-B1 | BENZAMIDE DERIVATIVES | TRANSLATIONAL GENOMICS RES INST (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2014102594-A2 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| EP-2485728-B1 | WNT PATHWAY ANTAGONISTS | SIENA BIOTECH SPA (IT) | 2013-07-10 | — | — | EP | disclosed |
| EP-1827678-B1 | METHOD AND APPARATUS FOR PERFORMING MICRO-SCALE CHEMICAL REACTIONS | TOTAL SYNTHESIS LTD (CA) | 2012-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169204-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | ATM 486/4885TDP1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.